

VACCINE

Continued from Page 18

less herpes virus with which most people are already infected. OHSU's CMV-based vaccine platform has already demonstrated promising pre-clinical efficacy against HIV and TB. The CMV-based HIV vaccine, for example, is headed into human clinical trials that will be managed by San Francisco-based Vir Biotechnology, which licensed the technology from OHSU.

So the million-dollar question is, will this new approach work? We'll test our CMV-based flu vaccine's effectiveness against one of the worst flu strains ever: the 1918 pandemic flu strain, which killed 50 million people worldwide. Within two years, we'll know if our CMV-based flu vaccine can fight off the 1918 flu strain. If it can beat that, it can probably beat any flu strain. And while we don't know for sure if it'll work, I'm proud to be part of this effort to help society once and for all beat the flu.




Ribonucleoprotein



Neuraminidase



Hemagglutinin



M2 ion channel

Courtesy of CDC



Warm-Water Pool

Outdoor Fitness Park

Excellent, Clean Facilities

Group Training

Personal Training

Nutritional Guidance

 **(541) 663-0462**

 **@mvtfitnessandhealth**

 **mountainvalleyfitness**